A 28-day, Double-blind, Randomized, Reference-controlled Psoriasis Plaque Test to Evaluate the Efficacy and Safety of Two Different BAY1003803 Formulation Types in 2 Concentrations Each in Treatment of Symptomatic Volunteers With Plaque-type Psoriasis
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs BAY 1003803 (Primary) ; Betamethasone/calcipotriol; Clobetasol
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors Bayer
- 20 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 23 Dec 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017.